Media headlines about BioScrip (NASDAQ:BIOS) have trended positive on Monday, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioScrip earned a news impact score of 0.35 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.9427291846902 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

A number of brokerages have commented on BIOS. Zacks Investment Research upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. BidaskClub upgraded shares of BioScrip from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. SunTrust Banks set a $4.00 price target on shares of BioScrip and gave the company a “buy” rating in a research report on Thursday, December 21st. Finally, ValuEngine upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $3.63.

BioScrip (NASDAQ BIOS) opened at $2.97 on Monday. BioScrip has a 52-week low of $1.35 and a 52-week high of $3.39. The company has a debt-to-equity ratio of -6.11, a quick ratio of 1.60 and a current ratio of 1.91. The company has a market cap of $378.72, a P/E ratio of -4.37 and a beta of 0.19.

TRADEMARK VIOLATION NOTICE: “BioScrip (BIOS) Given Daily News Sentiment Rating of 0.35” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Insider Buying and Selling by Quarter for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with's FREE daily email newsletter.